StockDuty ← Dashboard Sep 19, 2026 12:37 AM ET
SignalFDA/Bio

TAKEDA PHARMACEUTICAL (TAK) GETS PRIORITY REVIEW. CAN ZASOCITINIB WIN IN PSORIASIS? - YAHOO

Priority review for zasocitinib in psoriasis signals potential regulatory catalyst.

Priority review for zasocitinib in psoriasis signals potential regulatory catalyst.
Priority review for zasocitinib in psoriasis signals potential regulatory catalyst. — impact context not separately stored; see What changed.
Sources